Obesity
Cetero Research Uses Accelerated POC Study Design to Speed Drug Development; Cut Costs
Published in Drug Week, June 25th, 2010
Cetero Research, the leading early-stage contract research organization (CRO), announced its success in using an innovative approach to Phase I and Phase II clinical trials to cut study time by 50 percent and reduce costs by more than 10 percent. The accelerated POC (AcPOC) study design combines single ascending dose (SAD), multiple ascending dose (MAD), preliminary food effect, and proof-of-concept (POC) studies into one.
"There is tremendous pressure on pharmaceutical and biotech companies to save money while still providing safe and effective treatments. The accelerated proof-of-concept design helps assess drug candidates more quickly and at less cost," said Dr. Troy...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2010-06-25)
More Articles from Drug Week
- Drug Development
Cardium Announces Master Services Agreement With bioRASI for Planned Late-Stage Clinical Study and Commercialization Activities for Generx Product Candidate in International Markets - CombinatoRx, Incorporated
CombinatoRx Announces Date of Its 2010 Annual Meeting of Stockholders - Coagulation
Continuing Warfarin Therapy Proves Safe for Patients during Device Surgery - Corticosteroid
Data from D.W. Mapel et al provide new insights into corticosteroid - Central Nervous System
Data on central nervous system published by M. Maschio and colleagues - Defibrillators
Data on defibrillators discussed by researchers at University of Minnesota - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
